New shot may tame rare blood disease flares
NCT ID NCT04191304
First seen Jan 06, 2026 · Last updated May 21, 2026 · Updated 27 times
Summary
This study tests an injected drug called benralizumab in people with hypereosinophilic syndrome (HES), a rare condition where too many white blood cells cause organ damage. About 134 participants aged 12 and older will receive either benralizumab or a placebo every 4 weeks for 24 weeks, plus their usual treatments. The goal is to see if the drug delays or prevents disease flares, which are sudden worsening of symptoms requiring extra medication or hospital care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
La Jolla, California, 92037, United States
-
Research Site
Atlanta, Georgia, 30324, United States
-
Research Site
Bethesda, Maryland, 20892, United States
-
Research Site
Ann Arbor, Michigan, 48105, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Cleveland, Ohio, 44106, United States
-
Research Site
Columbus, Ohio, 43212, United States
-
Research Site
Salt Lake City, Utah, 84112, United States
-
Research Site
Rosario, 2000, Argentina
-
Research Site
Innsbruck, 6020, Austria
-
Research Site
Brussels, 1070, Belgium
-
Research Site
Edegem, 2650, Belgium
-
Research Site
Chengdu, 610041, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Xiamen, 361015, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
København Ø, 2100, Denmark
-
Research Site
Lille, 59037, France
-
Research Site
Pessac, 33604, France
-
Research Site
Strasbourg, 67091, France
-
Research Site
Suresnes, 92151, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Hanover, 30625, Germany
-
Research Site
Kirchheim, 73230, Germany
-
Research Site
Mannheim, 68167, Germany
-
Research Site
Ahmedabad, 380013, India
-
Research Site
Ajmer, 305001, India
-
Research Site
Delhi, 110029, India
-
Research Site
Haifa, 34362, Israel
-
Research Site
Holon, 58100, Israel
-
Research Site
Jerusalem, 91120, Israel
-
Research Site
Kfar Saba, 44218, Israel
-
Research Site
Petah Tikva, 49100, Israel
-
Research Site
Ramat Gan, 5265601, Israel
-
Research Site
Rehovot, 76100, Israel
-
Research Site
Tel Aviv, 64239, Israel
-
Research Site
Bologna, 40138, Italy
-
Research Site
Chiba, 260-0852, Japan
-
Research Site
Hamamatsu, 431-3192, Japan
-
Research Site
Ichikawa-shi, 272-8516, Japan
-
Research Site
Kawasaki-shi, 211-8510, Japan
-
Research Site
Nishinomiya-shi, 663-8501, Japan
-
Research Site
Osaka, 530-8480, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Rotterdam, 3015 GD, Netherlands
-
Research Site
Chęciny, 26-060, Poland
-
Research Site
Gdansk, 80-214, Poland
-
Research Site
Lodz, 90-153, Poland
-
Research Site
Seoul, 5505, South Korea
-
Research Site
Santander, 39010, Spain
-
Research Site
London, W2 1NY, United Kingdom
Conditions
Explore the condition pages connected to this study.